Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of oral ITF2357 in relapsed or refractory diffuse large B-cell lymphoma in patients older than 60 years
2006-002113-12Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma, sponsored by Italfarmaco. Primary endpoint: Objective response. Started Jan 2007; status: terminated.
02
Drugs
givinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2006-002113-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002113-12.